TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”) is pleased to announce the appointment of Paolo Toscano, P.Eng., as Vice President, Projects and Engineering, effective immediately. With more than three decades of experience leading large-scale mining and metals projects across North America, Mr. Toscano will oversee the construction and commissioning of North America’s first cobalt sulfate refinery in Temiskaming Shore ...

NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- eToro, the trading and investing platform, announced that it is bringing its patented CopyTrader™ technology to US users. From today, US users have the ability to instantly copy the investment strategies of real US traders across stocks, ETFs, or cryptoassets. “We are excited to bring one of eToro’s most recognized features to the world’s largest retail investing market. CopyTrader enables millions worldwide to replicate the trades of other investors and now Ameri ...

TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. ("ThreeD" or the "Company") (CSE:IDK) (OTCQX:IDKFF), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to congratulate HyperCycle on its recent announcement regarding the establishment of a $1.1 billion joint venture with a consortium of South Korean investors led by Addeep Inc. The joint venture aims to establish Seoul as a central hub ...

CHICAGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced its financial results for the third quarter ended September 30, 2025, which were prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”). Third Quarter 2025 Financial Highlights For the Three Months Ended,($ in thousands)September 30, 2025 June 30, 2025 September 30, 2024Revenues, net of Discounts ...

Company Invites Shareholders to Submit Questions to be Answered on the WebinarLOS ANGELES, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Playboy, Inc. (NASDAQ: PLBY) (the “Company” or “Playboy”), a leading pleasure and leisure lifestyle company, and one of the most recognizable and iconic brands in the world, today announced that it will release its financial results for its third quarter of 2025 on Wednesday, November 12, 2025, after the U.S. stock market closes. Playboy management will discuss those results and other ...

LONDON and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma, will present at the 33rd Annual BIO-Europe partnering conference in Vienna, Austria. BIO-Europe, one of the largest and most imp ...

Core Insights - Advent Technologies Holdings, Inc. is advancing the electrification of aviation through high-temperature proton exchange membrane fuel cells (HT-PEM FCs) in collaboration with aerospace partners [1][2] - The company’s proprietary Ion Pair™ membrane electrode assembly (MEA) enhances power output and thermal management efficiency, crucial for sustainable aviation [2][5] - Advent's HT-PEM technology allows for lighter and more compact aircraft designs, leading to improved performance and reduced operational costs [3][6] Company Overview - Advent Technologies is a leader in fuel cell and hydrogen technology, headquartered in Livermore, California, with a focus on renewable energy applications [1][6] - The company holds approximately 70 patents related to fuel cell technology, enabling high-temperature operations suitable for various sectors including aviation [6] Industry Context - Over 100 companies are engaged in developing electric flight solutions, with Advent providing essential technology for hydrogen-powered flight [2] - Stralis Aircraft, a partner of Advent, is pioneering hydrogen-powered fixed-wing aircraft, emphasizing the importance of advanced cooling systems for electric flight [3][4] - Liquid hydrogen offers a significant energy density advantage (approximately 33.3 kWh/kg) over lithium-ion batteries (around 0.3 kWh/kg), making it more suitable for long-range aviation applications [4]

Core Viewpoint - Chicago Atlantic BDC, Inc. is set to release its financial results for the third quarter of 2025 on November 13, 2025, before the market opens, followed by a conference call at 9:00 a.m. Eastern Time [1][2]. Company Overview - Chicago Atlantic BDC, Inc. is a specialty finance company regulated as a business development company under the Investment Company Act of 1940, focusing on maximizing risk-adjusted returns on equity for stockholders [4]. - The company's investment strategy primarily involves direct loans to privately held middle-market companies, with a significant emphasis on the cannabis sector [4]. Conference Call Details - The conference call will be accessible to the general public, with a dial-in number provided for participants [2][5]. - A replay of the conference call will be available on the company's website by the end of the day on November 13, 2025 [3].

Core Viewpoint - Beyond Meat has successfully completed an exchange offer for its existing 0% Convertible Senior Notes due 2027, allowing holders to exchange these notes for new 7.00% Convertible Senior Secured Second Lien PIK Toggle Notes due 2030 and shares of common stock, significantly reducing its outstanding debt and enhancing its capital structure [1][2][4]. Group 1: Exchange Offer Details - The exchange offer included up to $202.5 million in new convertible notes and up to 326,190,370 shares of common stock [1]. - As of the Early Tender Date on October 10, 2025, $1,114,603,000 in existing convertible notes were validly tendered [2]. - An additional $2,738,000 in existing convertible notes were tendered between the Early Tender Date and the Expiration Deadline on October 28, 2025 [3]. Group 2: Settlement Information - Early settlement occurred on October 15, 2025, with $208,717,000 in new convertible notes and 316,150,176 new shares issued [4]. - Following the final settlement on October 30, 2025, a total of $209,176,000 in new convertible notes and 316,926,786 new shares will have been issued [4]. - The total amount of tendered notes represents 97.16% of the outstanding principal amount of existing convertible notes, leaving $32,659,000 remaining [4]. Group 3: Eligibility and Regulatory Information - The new convertible notes and shares are offered only to "qualified institutional buyers" and "accredited investors" who own a minimum of $200,000 in existing convertible notes [5]. - The new convertible notes and shares have not been registered under the Securities Act of 1933, and the offer is not a solicitation to buy or sell any securities [6]. Group 4: Company Overview - Beyond Meat is a leading plant-based meat company focused on providing products made from simple ingredients without GMOs, hormones, or antibiotics [7]. - The company aims to replicate the taste and texture of animal-based meat while promoting health and environmental sustainability [7].

Core Insights - Seres Therapeutics has received up to $3.6 million in non-dilutive funding from CARB-X to support the development of an oral liquid formulation of SER-155, aimed at improving access for medically vulnerable patients, particularly those in intensive care who cannot take oral capsules [1][3][5] - SER-155 is being developed for patients undergoing allogeneic hematopoietic stem cell transplants (allo-HSCT) and has shown a 77% reduction in bacterial bloodstream infections (BSIs) compared to placebo in a Phase 1b study [2][5] - The development of a liquid formulation is expected to broaden the impact of SER-155 in additional high-risk patient populations susceptible to BSIs and antimicrobial resistant infections [3][5] Funding and Support - CARB-X, a global non-profit partnership, is providing funding to accelerate the development of antibacterial products, specifically targeting drug-resistant bacteria [1][4] - The funding is supported by various federal and international health organizations, including the U.S. Department of Health and Human Services and the UK Department of Health and Social Care [3][4] Clinical Development - SER-155 has received Breakthrough Therapy designation and Fast Track designation from the FDA, indicating its potential to significantly reduce the risk of infections in allo-HSCT patients [5][6] - The company is finalizing the clinical protocol for a well-powered, placebo-controlled Phase 2 study following positive feedback from the FDA [2][5] Company Background - Seres Therapeutics is focused on improving outcomes for medically vulnerable populations through live biotherapeutics and has previously developed VOWST™, the first FDA-approved orally administered microbiome therapeutic [5][6] - The company aims to evaluate SER-155 in various patient populations, including those undergoing autologous-HSCT, cancer patients with neutropenia, and patients in intensive care [6]